New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)

Rezultaty

KOL Engagement, Communication & Dissemination

Engagement, communication & dissemination of recent development and progress on ATXA’s lead drug NTP42 including with key opinion leaders (KOLs) and other stakeholders of relevance to pulmonary arterial hypertension (PAH).

Publikacje

Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Autorzy: Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Pedro Mendes-Ferreira, Rui Adão, Carmen Brás-Silva, B. Therese Kinsella
Opublikowane w: European Journal of Pharmacology, Numer 889, 2020, Strona(/y) 173658, ISSN 0014-2999
Wydawca: Elsevier BV
DOI: 10.1016/j.ejphar.2020.173658

Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation

Autorzy: Eamon P. Mulvaney, Áine G. O'Sullivan, Sarah B. Eivers, Helen M. Reid, B. Therese Kinsella
Opublikowane w: Experimental and Molecular Pathology, Numer 110, 2019, Strona(/y) 104277, ISSN 0014-4800
Wydawca: Academic Press
DOI: 10.1016/j.yexmp.2019.104277

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Autorzy: Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Annie Bouchard, Dany Salvail, B. Therese Kinsella
Opublikowane w: BMC Pulmonary Medicine, Numer 20/1, 2020, ISSN 1471-2466
Wydawca: BioMed Central
DOI: 10.1186/s12890-020-1113-2

NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

Autorzy: T Kinsella, E Mulvaney, HM Reid
Opublikowane w: European Respiratory Journal, 2019, Strona(/y) PA5048
Wydawca: European Respiratory Society

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Autorzy: T Kinsella, E Mulvaney, HM Reid
Opublikowane w: European Journal of Cardiology, Numer 40, 2019, Strona(/y) P3670
Wydawca: Oxford Academic

Prawa własności intelektualnej

THROMBOXANE RECEPTOR ANTAGONISTS

Numer wniosku/publikacji: 16 739541
Data: 2016-06-13
Wnioskodawca/wnioskodawcy: ATXA THERAPEUTICS LTD

Rezultaty

Publikacje

Prawa własności intelektualnej

Udostępnij tę stronę

Pobierz